Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's PCSK9 Patent Win: A Long-Term Value Shift?

This article was originally published in Scrip

Executive Summary

Amgen Inc. may have won a battle in its lawsuit involving two patents on its proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor Repatha (evolocumab) against Sanofi SA and Regeneron Pharmaceuticals Inc., which market a competing drug, Praluent (alirocumab), but the California biotech giant is far from winning the war – that is, making the prophesied blockbuster profits on its medicine.

Advertisement

Related Content

1Q Earnings Preview: What To Expect From US, EU Big Hitters
Advertisement
UsernamePublicRestriction

Register

SC064765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel